Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through studyMarc Ferrante, Luciana Teixeira de Campos, Geert D’Haens et al.|The Lancet|2024Cited by 107
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin‐Biroulet, Peter Bossuyt, Alessandro Armuzzi et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 96
Evaluation and Management of Glucocorticoid-Induced Adrenal Insufficiency in IBD: An Expert OpinionCindy C Y Law, Takayuki Yamamoto, Rachel Sheskier et al.|Inflammatory Bowel Diseases|2025Cited by 3